Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach

Julianne Duhazé, Miguel Caubet, Signe Hässler, Delphine Bachelet, Matthieu Allez, Florian Deisenhammer, Anna Fogdell-Hahn, Aude Gleizes, Salima Hacein-Bey-Abina, Xavier Mariette, Marc Pallardy, Philippe Broët, ABIRISK Consortium, Julianne Duhazé, Miguel Caubet, Signe Hässler, Delphine Bachelet, Matthieu Allez, Florian Deisenhammer, Anna Fogdell-Hahn, Aude Gleizes, Salima Hacein-Bey-Abina, Xavier Mariette, Marc Pallardy, Philippe Broët, ABIRISK Consortium

Abstract

Background: With the growth in use of biotherapic drugs in various medical fields, the occurrence of anti-drug antibodies represents nowadays a serious issue. This immune response against a drug can be due either to pre-existing antibodies or to the novel production of antibodies from B-cell clones by a fraction of the exposed subjects. Identifying genetic markers associated with the immunogenicity of biotherapeutic drugs may provide new opportunities for risk stratification before the introduction of the drug. However, real-world investigations should take into account that the population under study is a mixture of pre-immune, immune-reactive and immune-tolerant subjects.

Method: In this work, we propose a novel test for assessing the effect of genetic markers on drug immunogenicity taking into account that the population under study is a mixed one. This test statistic is derived from a novel two-part semiparametric improper survival model which relies on immunological mechanistic considerations.

Results: Simulation results show the good behavior of the proposed statistic as compared to a two-part logrank test. In a study on drug immunogenicity, our results highlighted findings that would have been discarded when considering classical tests.

Conclusion: We propose a novel test that can be used for analyzing drug immunogenicity and is easy to implement with standard softwares. This test is also applicable for situations where one wants to test the equality of improper survival distributions of semi-continuous outcomes between two or more independent groups.

Trial registration: ClinicalTrials.gov NCT02116504.

Keywords: Drug immunogenicity; Genetic; Semi-continuous data; Semi-parametric; Two-part improper survival model.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Survival curve of the fibroblast growth factor signaling pathway variant. We named ‘A’ the reference allele and ‘a’ the alternative allele

References

    1. Van de Weert M, Horn Moller E. Immunogenicity of biopharmaceuticals. New York: Springer; 2008.
    1. Pineda C, Castañeda Hernàndez G, Jacobs I, Alvarez D, Carini C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016;30(3):195–206. doi: 10.1007/s40259-016-0174-5.
    1. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–73. doi: 10.1208/s12248-014-9599-2.
    1. Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385–400. doi: 10.1111/cei.12652.
    1. Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment pnti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J. 2013;15(3):893–6. doi: 10.1208/s12248-013-9497-z.
    1. Farewell V, Long D, Tom B, Yiu S, Su L. Two-Part and related regression models for longitudinal data. Annu Rev Stat Appl. 2017;4:283–315. doi: 10.1146/annurev-statistics-060116-054131.
    1. Lachenbruch P. Comparisons of two-part models with competitors. Stat Med. 2001;20(8):1215–34. doi: 10.1002/sim.790.
    1. Maller R, Zhou X. Survival analysis with long-term survivors. New York: Wiley; 1997.
    1. Yakovlev A, Tsodikov A. Stochastic models of tumor latency and their biostatistical applications. Singapore: World Scientific; 1996.
    1. Tsodikov A, Ibrahim J, Yakovlev A. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003;764(98):1063–78. doi: 10.1198/01622145030000001007.
    1. ABIRISK: Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK. . Accessed 14 May 2019.
    1. Fleming T, Harrington D. Counting processes and survival analysis. New York: Wiley; 1991.
    1. Johnson N, Kemp A, Kotz S. Continuous univariate distributions. New York: Wiley; 2005.
    1. Cooner F, Banerjee S, Carlin BP, Sinha D. Flexible cure rate modeling under latent activation schemes. J Am Stat Assoc. 2007;102(478):560–72. doi: 10.1198/016214507000000112.
    1. Andersen P, Borgan O, Gill R, Keiding N. Statistical models based on counting processes. New York: Wiley; 1993.
    1. Cox D. Partial likelihood. Biometrika. 2001;62(2):269–76. doi: 10.1093/biomet/62.2.269.
    1. Nelson W. Theory and applications of hazard plotting for censored failure data. Technometrics. 1972;14:945–65. doi: 10.1080/00401706.1972.10488991.
    1. Dalmasso C, Broet P, Moreau T. A simple procedure for estimating the false discovery rate. Bioinformatics. 2005;21:660–8. doi: 10.1093/bioinformatics/bti063.
    1. Hu Z, Proschan M. Two-part test of vaccine effect: Z. HU AND M. PROSCHAN. Stat Med. 2015;34(11):1904–11. doi: 10.1002/sim.6412.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner